logo
logo

20N Bio Raises $3.3 Million In Series Seed Funding To Advance Computational Design Of New Proteins For Therapeutics

Dec 17, 2021•almost 4 years ago

Amount Raised

$3.3 Million

Round Type

seed

MalvernBiotechnologyScience And EngineeringHealth Care

Description

20n Bio (20n), an artificial intelligence (AI)-powered drug discovery company focusing on designing new proteins for therapeutics, has raised a $3.3 million seed round led by BlueRun Ventures China. 20n Bio will use the proceeds from the financing to expand its scientific team, establish a robust discovery platform, and start multiple early studies in oncology and other genetic diseases.

Company Information

Company

20n Bio

Location

Malvern, Pennsylvania, United States

About

20n Bio is a VC-backed start-up dedicated to the computational design of novel proteins for therapeutics. Launched in 2021 and located at Malvern PA, its mission is to in silico generate protein drugs with desired biophysical, functional, and pharmacological properties to address unmet medical needs. Learn more about 20n Bio by visiting http://www.20n.bio/ or following the company on LinkedIn.